Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×
“By midDecember, two mRNA vaccines had received emergency use authorization (EUA) by the Food and Drug Administration (FDA), both of which demonstrated approximately 95% efficacy against symptomatic COVID-19 in clinical trials (3, 4).”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 2×
“We aim to provide an estimate of vaccine effectiveness (VE) in the subpopulation of HCP reached through employer vaccination programs, to enrich the rapidly growing body of evidence in this area (5-7).”
Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00790-x · Cited by 767
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00448-7 · Cited by 306
Cited by
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,125
COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
CDC COVID-19 Vaccine Breakthrough Case Investigations Team, CDC COVID-19 Vaccine Breakthrough Case Investigations Team, Birhane, M., Bressler, S., Chang, G., Clark, T., Dorough, L., Fischer, M., Watkins, L. F., Goldstein, J. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7021e3 · Cited by 421
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00915-3 · Cited by 341
Chung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S. E., Chen, B., Calzavara, A., Fell, D. B., Austin, P. C., et al. (2021) · BMJ · doi:10.1136/bmj.n1943 · Cited by 307
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.017 · Cited by 254
“…Nasreen et al., 2021; Pawlowski et al., 2021; PHE, 2021; Pilishvili et al., 2021; Pritchard et al., 2021; Regev-Yochay et al., 2021; Sheikh et al., 2021; Stowe et al., 2021; Swift et al., 2021; Tande et al., 2021; Tang et al., 2021; Tenforde et al., 2021a, 2021b; Thompson et al., 2021a,…”
Metadata
- Authors
- Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., Murad, M. H., Berbari, E. F., & Virk, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-04-26
- Volume
- 73
- Issue
- 6
- Pages
- e1376-e1379
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3159334129
- Cited by
- 94
- References
- 6
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. https://app.cochat.ai/papers/10.1093/cid/ciab361
- The paper
- Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., Murad, M. H., Berbari, E. F., & Virk, A. (2021). Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.